TY - JOUR
T1 - Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma
AU - For The Multicenter Study Group Of Pancreatobiliary Surgery (Msg-Pbs)
AU - Motoi, Fuyuhiko
AU - Murakami, Yoshiaki
AU - Okada, Ken ichi
AU - Matsumoto, Ippei
AU - Uemura, Kenichiro
AU - Satoi, Sohei
AU - Sho, Masayuki
AU - Honda, Goro
AU - Fukumoto, Takumi
AU - Yanagimoto, Hiroaki
AU - Kinoshita, Shoichi
AU - Kurata, Masanao
AU - Aoki, Shuichi
AU - Mizuma, Masamichi
AU - Yamaue, Hiroki
AU - Unno, Michiaki
N1 - Funding Information:
Funding This work was supported in part by Grants-in-Aid for Scientific Research 24592018 and 16K10588 from the Japan Society for the Promotion of Science.
Publisher Copyright:
© 2018, Société Internationale de Chirurgie.
PY - 2019/2/15
Y1 - 2019/2/15
N2 - Background: Survival after surgery for pancreatic adenocarcinoma (PA) is poor and heterogeneous, even for curative (R0) resection. Serum carbohydrate antigen (CA) 19-9 levels are important prognostic markers for resected PA. However, sustained elevation of CA19-9 in association with the patterns of recurrence has been rarely investigated. Methods: Patients who underwent R0 resection (n = 539) were grouped according to postoperative serum CA19-9 levels (Group E: sustained elevation; Group N: no elevation). Clinicopathological factors, patterns of recurrence, and survival were compared between the groups. Results: Group E (n = 159) had significantly shorter median overall survival (17.1 vs. 35.4 months, p < 0.0001) than Group N (n = 380). Postoperative CA19-9 elevation was a significant independent predictor of poor survival in multivariate analysis (hazard ratio 1.98, p < 0.0001). The rate of hepatic recurrence in Group E was 2.6-fold higher than in Group N (45% vs. 17%, p < 0.0001). Postoperative CA19-9 elevation was a strongest independent predictor of primary hepatic recurrence (p < 0.0001) by a multiple regression model. Loco-regional, peritoneal, and other distant recurrence did not differ between the groups. The extent of preoperative CA19-9 elevation was correlated sustained elevation of CA19-9 after surgery (p < 0.0001) and primary hepatic recurrence (p = 0.0019). Conclusions: Sustained CA19-9 elevation was strong predictor of primary hepatic recurrence and short survival in cases of R0 resection for PA.
AB - Background: Survival after surgery for pancreatic adenocarcinoma (PA) is poor and heterogeneous, even for curative (R0) resection. Serum carbohydrate antigen (CA) 19-9 levels are important prognostic markers for resected PA. However, sustained elevation of CA19-9 in association with the patterns of recurrence has been rarely investigated. Methods: Patients who underwent R0 resection (n = 539) were grouped according to postoperative serum CA19-9 levels (Group E: sustained elevation; Group N: no elevation). Clinicopathological factors, patterns of recurrence, and survival were compared between the groups. Results: Group E (n = 159) had significantly shorter median overall survival (17.1 vs. 35.4 months, p < 0.0001) than Group N (n = 380). Postoperative CA19-9 elevation was a significant independent predictor of poor survival in multivariate analysis (hazard ratio 1.98, p < 0.0001). The rate of hepatic recurrence in Group E was 2.6-fold higher than in Group N (45% vs. 17%, p < 0.0001). Postoperative CA19-9 elevation was a strongest independent predictor of primary hepatic recurrence (p < 0.0001) by a multiple regression model. Loco-regional, peritoneal, and other distant recurrence did not differ between the groups. The extent of preoperative CA19-9 elevation was correlated sustained elevation of CA19-9 after surgery (p < 0.0001) and primary hepatic recurrence (p = 0.0019). Conclusions: Sustained CA19-9 elevation was strong predictor of primary hepatic recurrence and short survival in cases of R0 resection for PA.
UR - http://www.scopus.com/inward/record.url?scp=85054728577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054728577&partnerID=8YFLogxK
U2 - 10.1007/s00268-018-4814-4
DO - 10.1007/s00268-018-4814-4
M3 - Article
C2 - 30298281
AN - SCOPUS:85054728577
SN - 0364-2313
VL - 43
SP - 634
EP - 641
JO - World Journal of Surgery
JF - World Journal of Surgery
IS - 2
ER -